ADAR1 Capital Management, the largest stockholder of Keros Therapeutics (KROS) with approximately 13.3% of the Company’s outstanding shares, released an investor presentation outlining its rationale for withholding votes on the re-election of Dr. Mary Ann Gray and Dr. Alpna Seth to the Keros Board of Directors at the Company’s upcoming Annual Meeting of Stockholders, scheduled for June 4, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KROS:
- Keros Therapeutics price target lowered to $26 from $41 at Scotiabank
- Keros Therapeutics CEO to Speak at Healthcare Conference
- Keros Therapeutics price target lowered to $25 from $40 at H.C. Wainwright
- Keros Therapeutics: Buy Rating Affirmed Amid Promising Trial Data and Strategic Initiatives
- Keros Therapeutics Reports Strong Q1 2025 Results